Genetic variation: Effect on folate metabolism and health

Folate in Health and Disease, Second Edition

Volumn , Issue , 2009, Pages 75-110

  Christensen, Karen E ^a   Rozen, Rima ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85057908352     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (202)

1. Hoffbrand AV, Weir DG. The history of folic acid. Br J Haematol 2001; 113:579-89.
2. Leclerc D, Sibani S, Rozen R. Molecular biology of methylenetetrahydrofolate reductase (MTHFR) and overview of mutation/polymorphisms. In: Ueland PM, Rozen R, eds., MTHFR Polymorphisms and Disease. Georgetown, TX: Landes Bioscience, 2005:1-20.
3. Christensen KE, MacKenzie RE. Mitochondrial one-carbon metabolism is adapted to the specific needs of yeast, plants and mammals. Bioessays 2006; 28:595-605.
4. James SJ. The molecular dynamics of abnormal folate metabolism and DNA methy-lation: Implications for disease susceptibility and progression. In: Ueland PM, Rozen R, eds., MTHFR Polymorphisms and Disease. Georgetown, TX: Landes Bioscience, 2005:78-99.
5. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, Boers GJ, et al.A candidate genetic risk factor for vascular disease: A common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995; 10:111-13.
6. van der Put NM, Steegers-Theunissen RP, Frosst P, Trijbels FJ, Eskes TK, van den Heuvel LP, Mariman EC, den Heyer M, Rozen R, Blom HJ. Mutated methylenetetrahy-drofolate reductase as a risk factor for spina bifida. Lancet 1995; 346:1070-71.
7. Sunden SL, Renduchintala MS, Park EI, Miklasz SD, Garrow TA. Betaine-homocysteine methyltransferase expression in porcine and human tissues and chromosomal localization of the human gene. Arch Biochem Biophys 1997; 345:171-74.
8. Bao L, Vlcek C, Paces V, Kraus JP. Identification and tissue distribution of human cystathionine beta-synthase mRNA isoforms. Arch Biochem Biophys 1998; 350:95-103.
9. Database of Single Nucleotide Polymorphisms (dbSNP). Bethesda, MD: National Center for Biotechnology Information, National Library of Medicine (dbSNP Build ID: 129). Available at http://www.ncbi.nlm.nih.gov/SNP/.
10. Goyette P, Sumner JS, Milos R, Duncan AM, Rosenblatt DS, Matthews RG, Rozen R. Human methylenetetrahydrofolate reductase: Isolation of cDNA, mapping and mutation identification. Nat Genet 1994; 7:195-200.
11. Amorim MR, Lima MA, Castilla EE, Orioli IM. Non-Latin European descent could be a requirement for association of NTDs and MTHFR variant 677C ^ T: A meta-analysis. Am J Med Genet A 2007; 143A:1726-32.
12. Botto LD, Yang Q. 5,10-Methylenetetrahydrofolate reductase gene variants and congenital anomalies: A HuGE review. Am J Epidemiol 2000; 151:862-77.
13. Ogino S, Wilson RB. Genotype and haplotype distributions of MTHFR 677C^T and 1298A^C single nucleotide polymorphisms: A meta-analysis. J Hum Genet 2003; 48:1-7.
14. Sharp L, Little J. Polymorphisms in genes involved in folate metabolism and colorectal neoplasia: A HuGE review. Am J Epidemiol 2004; 159:423-43.
15. Yang QH, Botto LD, Gallagher M, Friedman JM, Sanders CL, Koontz D, Nikolova S, Erickson JD, Steinberg K. Prevalence and effects of gene-gene and gene-nutrient interactions on serum folate and serum total homocysteine concentrations in the United States: Findings from the Third National Health and Nutrition Examination Survey DNA Bank. Am J Clin Nutr 2008; 88:232-46.
16. Gueant-Rodriguez RM, Gueant JL, Debard R, Thirion S, Hong LX, Bronowicki JP, Namour F, et al. Prevalence of methylenetetrahydrofolate reductase 677T and 1298C alleles and folate status: A comparative study in Mexican, West African, and European populations. Am J Clin Nutr 2006; 83:701-07.
17. Yamada K, Chen Z, Rozen R, Matthews RG. Effects of common polymorphisms on the properties of recombinant human methylenetetrahydrofolate reductase. Proc Natl Acad Sci USA 2001; 98:14853-58.
18. van der Put NM, van den Heuvel LP, Steegers-Theunissen RP, Trijbels FJ, Eskes TK, Mariman EC, den Heyer M, Blom HJ. Decreased methylene tetrahydrofolate reductase activity due to the 677C^T mutation in families with spina bifida offspring. JMol Med 1996; 74:691-94.
19. Weisberg I, Tran P, Christensen B, Sibani S, Rozen R. A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Mol Genet Metab 1998; 64:169-72.
20. van der Put NM, Gabreels F, Stevens EM, Smeitink JA, Trijbels FJ, Eskes TK, van den Heuvel LP, Blom HJ. A second common mutation in the methylenetetrahydrofolate reductase gene: An additional risk factor for neural-tube defects? Am J Hum Genet 1998; 62:1044-51.
21. Jacques PF, Bostom AG, Williams RR, Ellison RC, Eckfeldt JH, Rosenberg IH, Selhub J, Rozen R. Relation between folate status, a common mutation in methylenetetrahydro-folate reductase, and plasma homocysteine concentrations. Circulation 1996; 93:7-9.
22. Davis SR, Quinlivan EP, Shelnutt KP, Maneval DR, Ghandour H, Capdevila A, Coats BS, et al. The methylenetetrahydrofolate reductase 677C^T polymorphism and dietary folate restriction affect plasma one-carbon metabolites and red blood cell folate concentrations and distribution in women. JNutr 2005; 135:1040-44.
23. Fredriksen A, Meyer K, Ueland PM, Vollset SE, Grotmol T, Schneede J. Large-scale population-based metabolic phenotyping of thirteen genetic polymorphisms related to one-carbon metabolism. Hum Mutat 2007; 28:856-65.
24. Hustad S, Midttun O, Schneede J, Vollset SE, Grotmol T, Ueland PM. The methylenetetrahydrofolate reductase 677C^T polymorphism as a modulator of a B vitamin network with major effects on homocysteine metabolism. Am J Hum Genet 2007; 80:846-55.
25. Devlin AM, Clarke R, Birks J, Evans JG, Halsted CH. Interactions among polymorphisms in folate-metabolizing genes and serum total homocysteine concentrations in a healthy elderly population. Am J Clin Nutr 2006; 83:708-13.
26. Jacques PF, Kalmbach R, Bagley PJ, Russo GT, Rogers G, Wilson PW, Rosenberg IH, Selhub J. The relationship between riboflavin and plasma total homocysteine in the Framingham offspring cohort is influenced by folate status and the C677T transition in the methylenetetrahydrofolate reductase gene. J Nutr 2002; 132:283-88.
27. Quinlivan EP, Davis SR, Shelnutt KP, Henderson GN, Ghandour H, Shane B, Selhub J, Bailey LB, Stacpoole PW, Gregory JF III. Methylenetetrahydrofolate reductase 677C^T polymorphism and folate status affect one-carbon incorporation into human DNA deoxynucleosides. J Nutr 2005; 135:389-96.
28. Bagley PJ, Selhub J. A common mutation in the methylenetetrahydrofolate reductase gene is associated with an accumulation of formylated tetrahydrofolates in red blood cells. Proc Natl Acad Sci USA 1998; 95:13217-20.
29. Friso S, Choi SW, Girelli D, Mason JB, Dolnikowski GG, Bagley PJ, Olivieri O, et al.A common mutation in the 5,10-methylenetetrahydrofolate reductase gene affects genomic DNA methylation through an interaction with folate status. Proc Natl Acad Sci USA 2002; 99:5606-11.
30. Molloy AM, Mills JL, Kirke PN, Whitehead AS, Weir DG, Scott JM. Whole-blood folate values in subjects with different methylenetetrahydrofolate reductase genotypes: Differences between the radioassay and microbiological assays. Clin Chem 1998; 44:186-88.
31. Jacques PF, Choumenkovitch SF. Mild MTHFR deficiency and folate status. In: Ueland PM, Rozen R, eds., MTHFR Polymorphisms and Disease. Georgetown, TX: Landes Bioscience, 2005:54-70.
32. Botto N, Andreassi MG, Manfredi S, Masetti S, Cocci F, Colombo MG, Storti S, Rizza A, Biagini A. Genetic polymorphisms in folate and homocysteine metabolism as risk factors for DNA damage. Eur J Hum Genet 2003; 11:671-78.
33. Shelnutt KP, Kauwell GP, Gregory JF 3rd, Maneval DR, Quinlivan EP, Theriaque DW, Henderson GN, Bailey LB. Methylenetetrahydrofolate reductase 677C^T polymorphism affects DNA methylation in response to controlled folate intake in young women. JNutr Biochem 2004; 15:554-60.
34. Vollset SE, Botto LD. Neural tube defects, other congenital malformations and single nucleotide polymorphisms in the 5,10 methylenetetrahydrofolate reductase (MTHFR) gene: A meta-analysis. In: Ueland PM, Rozen R, eds., MTHFR Polymorphisms and Disease. Georgetown, TX: Landes Bioscience, 2005:125-43.
35. Volcik KA, Shaw GM, Lammer EJ, Zhu H, Finnell RH. Evaluation of infant methyl-enetetrahydrofolate reductase genotype, maternal vitamin use, and risk of high versus low level spina bifida defects. Birth Defects Res A Clin Mol Teratol 2003; 67:154-57.
36. Wenstrom KD, Johanning GL, Owen J, Johnston KE, Acton S, Cliver S, Tamura T. Amniotic fluid homocysteine levels, 5,10-methylenetetrahydrafolate reductase genotypes, and neural tube closure sites. Am J Med Genet 2000; 90:6-11.
37. Relton CL, Wilding CS, Pearce MS, Laffling AJ, Jonas PA, Lynch SA, Tawn EJ, Burn J. Gene-gene interaction in folate-related genes and risk of neural tube defects in a UK population. J Med Genet 2004; 41:256-60.
38. Christensen B, Arbour L, Tran P, Leclerc D, Sabbaghian N, Platt R, Gilfix BM, et al.Genetic polymorphisms in methylenetetrahydrofolate reductase and methionine synthase, folate levels in red blood cells, and risk of neural tube defects. Am J Med Genet 1999; 84:151-57.
39. Shaw GM, Rozen R, Finnell RH, Wasserman CR, Lammer EJ. Maternal vitamin use, genetic variation of infant methylenetetrahydrofolate reductase, and risk for spina bifida. Am J Epidemiol 1998; 148:30-37.
40. Verkleij-Hagoort A, Bliek J, Sayed-Tabatabaei F, Ursem N, Steegers E, Steegers-Theunissen R. Hyperhomocysteinemia and MTHFR polymorphisms in association with orofacial clefts and congenital heart defects: A meta-analysis. Am J Med Genet A 2007; 143A:952-60.
41. van Beynum IM, den Heijer M, Blom HJ, Kapusta L. The MTHFR 677C^T polymorphism and the risk of congenital heart defects: A literature review and meta-analysis. QJM2007; 100:743-53.
42. van Beynum IM, Kapusta L, den Heijer M, Vermeulen SH, Kouwenberg M, Daniels O, Blom HJ. Maternal MTHFR 677C^T is a risk factor for congenital heart defects: Effect modification by periconceptional folate supplementation. Eur Heart J 2006; 27:981-87.
43. Junker R, Kotthoff S, Vielhaber H, Halimeh S, Kosch A, Koch HG, Kassenbohmer R, Heineking B, Nowak-Gottl U. Infant methylenetetrahydrofolate reductase 677TT genotype is a risk factor for congenital heart disease. Cardiovasc Res 2001; 51:251-54.
44. Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: Evidence on causality from a meta-analysis. BMJ 2002; 325:1202.
45. Klerk M, Verhoef P, Clarke R, Blom HJ, Kok FJ, Schouten EG. MTHFR 677C^T polymorphism and risk of coronary heart disease: A meta-analysis. JAMA 2002; 288:2023-31.
46. Lewis SJ, Ebrahim S, Davey Smith G. Meta-analysis of MTHFR 677C^T polymorphism and coronary heart disease: Does totality of evidence support causal role for homocysteine and preventive potential of folate? BMJ 2005; 331:1053.
47. Girelli D, Martinelli N, Pizzolo F, Friso S, Olivieri O, Stranieri C, Trabetti E, et al. The interaction between MTHFR 677 C^T genotype and folate status is a determinant of coronary atherosclerosis risk. J Nutr 2003; 133:1281-85.
48. Mager A, Lalezari S, Shohat T, Birnbaum Y, Adler Y, Magal N, Shohat M. Methylenetetrahydrofolate reductase genotypes and early-onset coronary artery disease. Circulation 1999; 100:2406-10.
49. Rallidis LS, Gialeraki A, Komporozos C, Vavoulis P, Pavlakis G, Travlou A, Lekakis I, Kremastinos DT. Role of methylenetetrahydrofolate reductase 677C^T polymorphism in the development of premature myocardial infarction. Atherosclerosis 2008; 200:115-20.
50. Gemmati D, Serino ML, Trivellato C, Fiorini S, Scapoli GL. C677T substitution in the methylenetetrahydrofolate reductase gene as a risk factor for venous thrombosis and arterial disease in selected patients. Haematologica 1999; 84:824-28.
51. Cronin S, Furie KL, Kelly PJ. Dose-related association of MTHFR 677T allele with risk of ischemic stroke: Evidence from a cumulative meta-analysis. Stroke 2005; 36:1581-87.
52. Casas JP, Bautista LE, Smeeth L, Sharma P, Hingorani AD. Homocysteine and stroke: Evidence on a causal link from mendelian randomisation. Lancet 2005; 365:224-32.
53. Ray JG, Shmorgun D, Chan WS. Common C677T polymorphism of the methylenetet-rahydrofolate reductase gene and the risk of venous thromboembolism: Meta-analysis of 31 studies. Pathophysiol Haemost Thromb 2002; 32:51-58.
54. Den Heijer M, Lewington S, Clarke R. Homocysteine, MTHFR and risk of venous thrombosis: A meta-analysis of published epidemiological studies. J Thromb Haemost2005; 3:292-99.
55. Chen J, Giovannucci E, Kelsey K, Rimm EB, Stampfer MJ, Colditz GA, Spiegelman D, Willett WC, Hunter DJ. A methylenetetrahydrofolate reductase polymorphism and the risk of colorectal cancer. Cancer Res 1996; 56:4862-64.
56. Ma J, Stampfer MJ, Giovannucci E, Artigas C, Hunter DJ, Fuchs C, Willett WC, Selhub J, Hennekens CH, Rozen R. Methylenetetrahydrofolate reductase polymorphism, dietary interactions, and risk of colorectal cancer. Cancer Res 1997; 57:1098-102.
57. Crott JW, Mason JB. MTHFR polymorphisms and colorectal neoplasia. In: Ueland PM, Rozen R, eds., MTHFR Polymorphisms and Disease. Georgetown, TX: Landes Bioscience, 2005:179-96.
58. Blount BC, Mack MM, Wehr CM, MacGregor JT, Hiatt RA, Wang G, Wickramasinghe SN, Everson RB, Ames BN. Folate deficiency causes uracil misincorporation into human DNA and chromosome breakage: Implications for cancer and neuronal damage. Proc Natl Acad Sci USA 1997; 94:3290-95.
59. Huang Y, Han S, Li Y, Mao Y, Xie Y. Different roles of MTHFR C677T and A1298C polymorphisms in colorectal adenoma and colorectal cancer: A meta-analysis. J Hum Genet 2007; 52:73-85.
60. Le Marchand L, Donlon T, Hankin JH, Kolonel LN, Wilkens LR, Seifried A. B-vitamin intake, metabolic genes, and colorectal cancer risk (United States). Cancer Causes Control 2002; 13:239-48.
61. Toffoli G, Gafa R, Russo A, Lanza G, Dolcetti R, Sartor F, Libra M, Viel A, Boiocchi M. Methylenetetrahydrofolate reductase 677 C^T polymorphism and risk of proximal colon cancer in north Italy. Clin Cancer Res 2003; 9:743-48.
62. Boccia S, Hung R, Ricciardi G, Gianfagna F, Ebert MP, Fang JY, Gao CM, et al.Meta- and pooled analyses of the methylenetetrahydrofolate reductase C677T and A1298C polymorphisms and gastric cancer risk: A huge-GSEC review. Am J Epidemiol2008; 167:505-16.
63. Sun L, Sun YH, Wang B, Cao HY, Yu C. Methylenetetrahydrofolate reductase polymorphisms and susceptibility to gastric cancer in Chinese populations: A meta-analysis.Eur J Cancer Prev 2008; 17:446-52.
64. Muntjewerff JW, Kahn RS, Blom HJ, den Heijer M. Homocysteine, methylenetetrahy-drofolate reductase and risk of schizophrenia: A meta-analysis. Mol Psychiatry 2006; 11:143-49.
65. Gilbody S, Lewis S, Lightfoot T. Methylenetetrahydrofolate reductase (MTHFR) genetic polymorphisms and psychiatric disorders: A HuGE review. Am J Epidemiol 2007; 165:1-13.
66. Nelen WL, Blom HJ, Steegers EA, den Heijer M, Eskes TK. Hyperhomocysteinemia and recurrent early pregnancy loss: A meta-analysis. Fertil Steril 2000; 74:1196-99.
67. Kosmas IP, Tatsioni A, Ioannidis JP. Association of C677T polymorphism in the methyl-enetetrahydrofolate reductase gene with hypertension in pregnancy and pre-eclampsia: A meta-analysis. J Hypertens 2004; 22:1655-62.
68. Schwahn BC, Rozen R. Methylenetetrahydrofolate reductase polymorphisms: Pharmacogenetic effects. In: Ueland PM, Rozen R, eds., MTHFR Polymorphisms and Disease. Georgetown, TX: Landes Bioscience, 2005:197-205.
69. Brown NM, Pratt VM, Buller A, Pike-Buchanan L, Redman JB, Sun W, Chen R, et al.Detection of 677CT/1298AC “double variant” chromosomes: Implications for interpretation of MTHFR genotyping results. Genet Med 2005; 7:278-82.
70. Weisberg IS, Jacques PF, Selhub J, Bostom AG, Chen Z, Curtis Ellison R, Eckfeldt JH, Rozen R. The 1298A^C polymorphism in methylenetetrahydrofolate reductase (MTHFR): In vitro expression and association with homocysteine. Atherosclerosis2001; 156:409-15.
71. Parle-McDermott A, Mills JL, Kirke PN, O’Leary VB, Swanson DA, Pangilinan F, Conley M, et al. Analysis of the MTHFR 1298A^C and 677C^T polymorphisms as risk factors for neural tube defects. J Hum Genet 2003; 48:190-93.
72. Relton CL, Wilding CS, Laffling AJ, Jonas PA, Burgess T, Binks K, Tawn EJ, Burn J. Low erythrocyte folate status and polymorphic variation in folate-related genes are associated with risk of neural tube defect pregnancy. Mol Genet Metab 2004; 81:273-81.
73. Hanson NQ, Aras O, Yang F, Tsai MY. C677T and A1298C polymorphisms of the methylenetetrahydrofolate reductase gene: Incidence and effect of combined genotypes on plasma fasting and post-methionine load homocysteine in vascular disease. Clin Chem 2001; 47:661-66.
74. Ray JG, Langman LJ, Vermeulen MJ, Evrovski J, Yeo EL, Cole DE. Genetics University of Toronto Thrombophilia Study in Women (GUTTSI): Genetic and other risk factors for venous thromboembolism in women. Curr Control Trials Cardiovasc Med 2001; 2:141-49.
75. Chen Z, Karaplis AC, Ackerman SL, Pogribny IP, Melnyk S, Lussier-Cacan S, Chen MF, et al. Mice deficient in methylenetetrahydrofolate reductase exhibit hyperhomo-cysteinemia and decreased methylation capacity, with neuropathology and aortic lipid deposition. Hum Mol Genet 2001; 10:433-43.
76. Celtikci B, Leclerc D, Lawrance AK, Deng L, Friedman HC, Krupenko NI, Krupenko SA, et al. Altered expression of methylenetetrahydrofolate reductase modifies response to methotrexate in mice. Pharmacogenet Genom 2008; 18:577-89.
77. Schwahn BC, Chen Z, Laryea MD, Wendel U, Lussier-Cacan S, Genest JJ, Mar M-H, et al. Homocysteine-betaine interactions in a murine model of 5,10-methylene tetra-hydrofolate reductase deficiency. FASEB J 2003; 17:512-14.
78. Li D, Pickell L, Liu Y, Wu Q, Cohn JS, Rozen R. Maternal methylenetetrahydrofolate reductase deficiency and low dietary folate lead to adverse reproductive outcomes and congenital heart defects in mice. Am J Clin Nutr 2005; 82:188-95.
79. Schwahn BC, Wang XL, Mikael LG, Wu Q, Cohn J, Jiang H, Maclean KN, Rozen R. Betaine supplementation improves the atherogenic risk factor profile in a transgenic mouse model of hyperhomocysteinemia. Atherosclerosis 2007; 195:e100-07.
80. Schwahn BC, Laryea MD, Chen Z, Melnyk S, Pogribny I, Garrow T, James SJ, Rozen R. Betaine rescue of an animal model with methylenetetrahydrofolate reductase deficiency. Biochem J 2004; 382:831-40.
81. Ghandour H, Chen Z, Selhub J, Rozen R. Mice deficient in methylenetetrahy-drofolate reductase exhibit tissue-specific distribution of folates. J Nutr 2004; 134:2975-78.
82. Li D, Karp N, Wu Q, Wang XL, Melnyk S, James SJ, Rozen R. Mefolinate (5-methyltetrahydrofolate), but not folic acid, decreases mortality in an animal model of severe methylenetetrahydrofolate reductase deficiency. J Inherit Metab Dis 2008; 31:403-11.
83. Virdis A, Iglarz M, Neves MF, Amiri F, Touyz RM, Rozen R, Schiffrin EL. Effect of hyperhomocystinemia and hypertension on endothelial function in methylenetetrahy-drofolate reductase-deficient mice. Arterioscler Thromb Vasc Biol 2003; 23:1352-57.
84. Neves MF, Endemann D, Amiri F, Virdis A, Pu Q, Rozen R, Schiffrin EL. Small artery mechanics in hyperhomocysteinemic mice: Effects of angiotensin II. J Hypertens 2004; 22:959-66.
85. Mikael LG, Genest J Jr, Rozen R. Elevated homocysteine reduces apolipoprotein A-I expression in hyperhomocysteinemic mice and in males with coronary artery disease. Circ Res 2006; 98:564-71.
86. Knock E, Deng L, Wu Q, Leclerc D, Wang XL, Rozen R. Low dietary folate initiates intestinal tumors in mice, with altered expression of G2-M checkpoint regulators polo-like kinase 1 and cell division cycle 25c. Cancer Res 2006; 66:10349-56.
87. Mikael LG, Rozen R. Homocysteine modulates the effect of simvastatin on expression of ApoA-I and NF-KB/iNOS. Cardiovasc Res 2008; 80:151-58.
88. Roy M, Leclerc D, Wu Q, Gupta S, Kruger WD, Rozen R. Valproic acid increases expression of methylenetetrahydrofolate reductase (MTHFR) and induces lower teratogenicity in MTHFR deficiency. J Cell Biochem 2008; 105:467-76.
89. Chen LH, Liu M-L, Hwang H-Y, Chen L-S, Korenberg J, Shane B. Human methionine synthase. cDNA cloning, gene localization, and expression. J Biol Chem 1997; 272:3628-34.
90. Olteanu H, Munson T, Banerjee R. Differences in the efficiency of reductive activation of methionine synthase and exogenous electron acceptors between the common polymorphic variants of human methionine synthase reductase. Biochemistry 2002; 41:13378-85.
91. van der Put NM, van der Molen EF, Kluijtmans LA, Heil SG, Trijbels JM, Eskes TK, Van Oppenraaij-Emmerzaal D, Banerjee R, Blom HJ. Sequence analysis of the coding region of human methionine synthase: Relevance to hyperhomocysteinaemia in neuraltube defects and vascular disease. QJM 1997; 90:511-17.
92. Theodoratou E, Farrington SM, Tenesa A, McNeill G, Cetnarskyj R, Barnetson RA, Porteous ME, Dunlop MG, Campbell H. Dietary vitamin B6 intake and the risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev 2008; 17:171-82.
93. Koushik A, Kraft P, Fuchs CS, Hankinson SE, Willett WC, Giovannucci EL, Hunter DJ. Nonsynonymous polymorphisms in genes in the one-carbon metabolism pathway and associations with colorectal cancer. Cancer Epidemiol Biomarkers Prev 2006; 15:2408-17.
94. Chen J, Stampfer MJ, Ma J, Selhub J, Malinow MR, Hennekens CH, Hunter DJ. Influence of a methionine synthase (D919G) polymorphism on plasma homocysteine and folate levels and relation to risk of myocardial infarction. Atherosclerosis 2001; 154:667-72.
95. Ma J, Stampfer MJ, Christensen B, Giovannucci E, Hunter DJ, Chen J, Willett WC, et al. A polymorphism of the methionine synthase gene: Association with plasma folate, vitamin B12, homocyst(e)ine, and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev 1999; 8:825-29.
96. Klerk M, Lievers KJ, Kluijtmans LA, Blom HJ, den Heijer M, Schouten EG, Kok FJ, Verhoef P. The 2756A^G variant in the gene encoding methionine synthase: Its relation with plasma homocysteine levels and risk of coronary heart disease in a Dutch case-control study. Thromb Res 2003; 110:87-91.
97. Gueant-Rodriguez RM, Juilliere Y, Candito M, Adjalla CE, Gibelin P, Herbeth B, Van Obberghen E, Gueant JL. Association of MTRRA66G polymorphism (but not of MTHFR C677T and A1298C, MTRA2756G, TCN C776G) with homocysteine and coronary artery disease in the French population. Thromb Haemost 2005; 94:510-15.
98. Ulvik A, Vollset SE, Hansen S, Gislefoss R, Jellum E, Ueland PM. Colorectal cancer and the methylenetetrahydrofolate reductase 677C^T and methionine synthase 2756A^G polymorphisms: A study of 2,168 case-control pairs from the JANUS cohort. Cancer Epidemiol Biomarkers Prev 2004; 13:2175-80.
99. Zhu H, Wicker NJ, Shaw GM, Lammer EJ, Hendricks K, Suarez L, Canfield M, Finnell RH. Homocysteine remethylation enzyme polymorphisms and increased risks for neural tube defects. Mol Genet Metab 2003; 78:216-21.
100. van der Linden IJ, den Heijer M, Afman LA, Gellekink H, Vermeulen SH, Kluijtmans LA, Blom HJ. The methionine synthase reductase 66A^G polymorphism is a maternal risk factor for spina bifida. J Mol Med 2006; 84:1047-54.
101. Zhang G, Dai C. Gene polymorphisms of homocysteine metabolism-related enzymes in Chinese patients with occlusive coronary artery or cerebral vascular diseases. Thromb Res 2001; 104:187-95.
102. Ulrich CM, Curtin K, Potter JD, Bigler J, Caan B, Slattery ML. Polymorphisms in the reduced folate carrier, thymidylate synthase, or methionine synthase and risk of colon cancer. Cancer Epidemiol Biomarkers Prev 2005; 14:2509-16.
103. Hazra A, Wu K, Kraft P, Fuchs CS, Giovannucci EL, Hunter DJ. Twenty-four nonsynonymous polymorphisms in the one-carbon metabolic pathway and risk of colorectal adenoma in the Nurses’ Health Study. Carcinogenesis 2007; 28:1510-19.
104. Bosco P, Gueant-Rodriguez RM, Anello G, Romano A, Namour B, Spada RS, Caraci F, Tringali G, Ferri R, Gueant JL. Association of IL-1 RN*2 allele and methionine synthase 2756 AA genotype with dementia severity of sporadic Alzheimer’s disease. J Neurol Neurosurg Psychiatry 2004; 75:1036-38.
105. Beyer K, Lao JI, Latorre P, Ariza A. Age at onset: An essential variable for the definition of genetic risk factors for sporadic Alzheimer’s disease. Ann N Y Acad Sci 2005; 1057:260-78.
106. Swanson DA, Liu ML, Baker PJ, Garrett L, Stitzel M, Wu J, Harris M, Banerjee R, Shane B, Brody LC. Targeted disruption of the methionine synthase gene in mice. Mol Cell Biol 2001; 21:1058-65.
107. Dayal S, Devlin AM, McCaw RB, Liu M-L, Arning E, Bottiglieri T, Shane B, Faraci FM, Lentz SR. Cerebral vascular dysfunction in methionine synthase-deficient mice. Circulation 2005; 112:737-44.
108. Yamada K, Gravel RA, Toraya T, Matthews RG. Human methionine synthase reductase is a molecular chaperone for human methionine synthase. Proc Natl Acad Sci USA 2006; 103:9476-81.
109. Wilson A, Platt R, Wu Q, Leclerc D, Christensen B, Yang H, Gravel RA, Rozen R. A common variant in methionine synthase reductase combined with low cobalamin (vitamin B12) increases risk for spina bifida. Mol Genet Metab 1999; 67:317-23.
110. Shi M, Caprau D, Romitti P, Christensen K, Murray JC. Genotype frequencies and linkage disequilibrium in the CEPH human diversity panel for variants in folate pathway genes MTHFR, MTHFD, MTRR, RFC1, and GCP2. Birth Defects Res A Clin Mol Teratol 2003; 67:545-49.
111. Olteanu H, Wolthers KR, Munro AW, Scrutton NS, Banerjee R. Kinetic and thermodynamic characterization of the common polymorphic variants of human methionine synthase reductase. Biochemistry 2004; 43:1988-97.
112. Wolthers KR, Scrutton NS. Protein interactions in the human methionine synthase-methionine synthase reductase complex and implications for the mechanism of enzyme reactivation. Biochemistry 2007; 46:6696-709.
113. Brown CA, McKinney KQ, Kaufman JS, Gravel RA, Rozen R. A common polymorphism in methionine synthase reductase increases risk of premature coronary artery disease. J Cardiovasc Risk 2000; 7:197-200.
114. Brilakis ES, Berger PB, Ballman KV, Rozen R. Methylenetetrahydrofolate reductase (MTHFR) 677C^T and methionine synthase reductase (MTRR) 66A^G polymorphisms: Association with serum homocysteine and angiographic coronary artery disease in the era of flour products fortified with folic acid. Atherosclerosis 2003; 168:315-22.
115. Barbosa PR, Stabler SP, Trentin R, Carvalho FR, Luchessi AD, Hirata RD, Hirata MH, Allen RH, Guerra-Shinohara EM. Evaluation of nutritional and genetic determinants of total homocysteine, methylmalonic acid and S-adenosylmethionine/S-adenosylhomocysteine values in Brazilian childbearing-age women. Clin Chim Acta2008; 388:139-47.
116. Gaughan DJ, Kluijtmans LA, Barbaux S, McMaster D, Young IS, Yarnell JW, Evans A, Whitehead AS. The methionine synthase reductase (MTRR) A66G polymorphism is a novel genetic determinant of plasma homocysteine concentrations. Atherosclerosis2001; 157:451-56.
117. Verkleij-Hagoort AC, van Driel LM, Lindemans J, Isaacs A, Steegers EA, Helbing WA, Uitterlinden AG, Steegers-Theunissen RP. Genetic and lifestyle factors related to the periconception vitamin B12 status and congenital heart defects: A Dutch case-control study. Mol Genet Metab 2008; 94:112-19.
118. van Beynum IM, Kouwenberg M, Kapusta L, den Heijer M, van der Linden IJ, Daniels O, Blom HJ. MTRR 66A^G polymorphism in relation to congenital heart defects. Clin Chem Lab Med 2006; 44:1317-23.
119. Shi Q, Zhang Z, Li G, Pillow PC, Hernandez LM, Spitz MR, Wei Q. Polymorphisms of methionine synthase and methionine synthase reductase and risk of lung cancer: A case-control analysis. Pharmacogenet Genomics 2005; 15:547-55.
120. Elmore CL, Wu X, Leclerc D, Watson ED, Bottiglieri T, Krupenko NI, Krupenko SA, et al. Metabolic derangement of methionine and folate metabolism in mice deficient in methionine synthase reductase. Mol Genet Metab 2007; 91:85-97.
121. Deng L, Elmore CL, Lawrance AK, Matthews RG, Rozen R. Methionine synthase reductase deficiency results in adverse reproductive outcomes and congenital heart defects in mice. Mol Genet Metab 2008; 94:336-42.
122. Hum DW, MacKenzie RE. Expression of active domains of a human folate-dependent trifunctional enzyme in Escherichia coli. Protein Eng 1991; 4:493-500.
123. Hol FA, van der Put NM, Geurds MP, Heil SG, Trijbels FJ, Hamel BC, Mariman EC, Blom HJ. Molecular genetic analysis of the gene encoding the trifunctional enzyme MTHFD (methylenetetrahydrofolate-dehydrogenase, methenyltetrahydrofolate-cyclo-hydrolase, formyltetrahydrofolate synthetase) in patients with neural tube defects. Clin Genet 1998; 53:119-25.
124. Brody LC, Conley M, Cox C, Kirke PN, McKeever MP, Mills JL, Molloy AM, et al.A polymorphism, R653Q, in the trifunctional enzyme methylenetetrahydrofolate dehydrogenase/methenyltetrahydrofolate cyclohydrolase/formyltetrahydrofolate synthetase is a maternal genetic risk factor for neural tube defects: Report of the Birth Defects Research Group. Am J Hum Genet 2002; 71:1207-15.
125. Chen J, Kyte C, Valcin M, Chan W, Wetmur JG, Selhub J, Hunter DJ, Ma J. Polymorphisms in the one-carbon metabolic pathway, plasma folate levels and colorectal cancer in a prospective study. Int J Cancer 2004; 110:617-20.
126. Parle-McDermott A, Mills JL, Kirke PN, Cox C, Signore CC, Kirke S, Molloy AM, et al.MTHFD1 R653Q polymorphism is a maternal genetic risk factor for severe abruptio placentae. Am J Med Genet A 2005; 132:365-68.
127. Parle-McDermott A, Pangilinan F, Mills JL, Signore CC, Molloy AM, Cotter A, Conley M, et al. A polymorphism in the MTHFD1 gene increases a mother’s risk of having an unexplained second trimester pregnancy loss. Mol Hum Reprod 2005; 11:477-80.
128. De Marco P, Merello E, Calevo MG, Mascelli S, Raso A, Cama A, Capra V. Evaluation of a methylenetetrahydrofolate-dehydrogenase 1958G^A polymorphism for neural tube defect risk. J Hum Genet 2006; 51:98-103.
129. van der Linden IJ, Heil SG, Kouwenberg IC, den Heijer M, Blom HJ. The methyle-netetrahydrofolate dehydrogenase (MTHFD1) 1958G^A variant is not associated with spina bifida risk in the Dutch population. Clin Genet 2007; 72:599-600.
130. Cheng J, Zhu WL, Dao JJ, Li SQ, Li Y. Relationship between polymorphism of methyl-enetetrahydrofolate dehydrogenase and congenital heart defect. Biomed Environ Sci2005; 18:58-64.
131. Wang L, Ke Q, Chen W, Wang J, Tan Y, Zhou Y, Hua Z, et al. Polymorphisms of MTHFD, plasma homocysteine levels, and risk of gastric cancer in a high-risk Chinese population. Clin Cancer Res 2007; 13:2526-32.
132. Christensen KE, Rohlicek CV, Andelfinger GU, Michaud J, Bigras JL, Richter A, Mackenzie RE, Rozen R. The MTHFD1 p.Arg653Gln variant alters enzyme function and increases risk for congenital heart defects. Hum Mutat 2009; 30:212-20.
133. Kohlmeier M, da Costa KA, Fischer LM, Zeisel SH. Genetic variation of folate-mediated one-carbon transfer pathway predicts susceptibility to choline deficiency in humans. Proc Natl Acad Sci USA 2005; 102:16025-30.
134. Parle-McDermott A, Kirke PN, Mills JL, Molloy AM, Cox C, O’Leary VB, Pangilinan F, et al. Confirmation of the R653Q polymorphism of the trifunctional C1-synthase enzyme as a maternal risk for neural tube defects in the Irish population. Eur J Hum Genet 2006; 14:768-72.
135. Scala I, Granese B, Sellitto M, Salome S, Sammartino A, Pepe A, Mastroiacovo P, Sebastio G, Andria G. Analysis of seven maternal polymorphisms of genes involved in homocysteine/folate metabolism and risk of Down syndrome offspring. Genet Med2006; 8:409-16.
136. Stevens VL, McCullough ML, Pavluck AL, Talbot JT, Feigelson HS, Thun MJ, Calle EE. Association of polymorphisms in one-carbon metabolism genes and postmenopausal breast cancer incidence. Cancer Epidemiol Biomarkers Prev 2007; 16:1140-47.
137. Oterino A, Valle N, Pascual J, Bravo Y, Munoz P, Castillo J, Ruiz-Alegria C, Sanchez-Velasco P, Leyva-Cobian F, Cid C. Thymidylate synthase promoter tandem repeat and MTHFD1 R653Q polymorphisms modulate the risk for migraine conferred by the MTHFR T677 allele. Mol Brain Res 2005; 139:163-68.
138. Krajinovic M, Lemieux-Blanchard E, Chiasson S, Primeau M, Costea I, Moghrabi A. Role of polymorphisms in MTHFR and MTHFD1 genes in the outcome of childhood acute lymphoblastic leukemia. Pharmacogenomics J 2004; 4:66-72.
139. Woeller CF, Anderson DD, Szebenyi DM, Stover PJ. Evidence for small ubiquitin-like modifier-dependent nuclear import of the thymidylate biosynthesis pathway. J Biol Chem 2007; 282:17623-31.
140. Herbig K, Chiang EP, Lee LR, Hills J, Shane B, Stover PJ. Cytoplasmic serine hydroxymethyltransferase mediates competition between folate-dependent deoxyribo-nucleotide and S-adenosylmethionine biosyntheses. J Biol Chem 2002; 277:38381-89.
141. Heil SG, Van der Put NM, Waas ET, den Heijer M, Trijbels FJ, Blom HJ. Is mutated serine hydroxymethyltransferase (SHMT) involved in the etiology of neural tube defects? Mol Genet Metab 2001; 73:164-72.
142. Girgis S, Nasrallah IM, Suh JR, Oppenheim E, Zanetti KA, Mastri MG, Stover PJ. Molecular cloning, characterization and alternative splicing of the human cytoplasmic serine hydroxymethyltransferase gene. Gene 1998; 210:315-24.
143. van den Donk M, Visker MH, Harryvan JL, Kok FJ, Kampman E. Dietary intake of B-vitamins, polymorphisms in thymidylate synthase and serine hydroxymethyltrans-ferase 1, and colorectal adenoma risk: A Dutch case-control study. Cancer Lett 2007; 250:146-53.
144. Engel SM, Olshan AF, Siega-Riz AM, Savitz DA, Chanock SJ. Polymorphisms in folate metabolizing genes and risk for spontaneous preterm and small-for-gestational age birth. Am J Obstet Gynecol 2006; 195:1231 e1-11.
145. Hishida A, Matsuo K, Hamajima N, Ito H, Ogura M, Kagami Y, Taji H, Morishima Y, Emi N, Tajima K. Associations between polymorphisms in the thymidylate synthase and serine hydroxymethyltransferase genes and susceptibility to malignant lymphoma. Haematologica 2003; 88:159-66.
146. Cheng CW, Yu JC, Huang CS, Shieh JC, Fu YP, Wang HW, Wu PE, Shen CY. Polymorphism of cytosolic serine hydroxymethyltransferase, estrogen and breast cancer risk among Chinese women in Taiwan. Breast Cancer Res Treat 2008; 111:145-55.
147. Fu TF, Hunt S, Schirch V, Safo MK, Chen BH. Properties of human and rabbit cytosolic serine hydroxymethyltransferase are changed by single nucleotide polymorphic mutations. Arch Biochem Biophys 2005; 442:92-101.
148. Lim U, Peng K, Shane B, Stover PJ, Litonjua AA, Weiss ST, Gaziano JM, et al.Polymorphisms in cytoplasmic serine hydroxymethyltransferase and methylenetetra-hydrofolate reductase affect the risk of cardiovascular disease in men. J Nutr 2005; 135:1989-94.
149. MacFarlane AJ, Liu X, Perry CA, Flodby P, Allen RH, Stabler SP, Stover PJ. Cytoplasmic serine hydroxymethyltransferase regulates the metabolic partitioning of methylenetetra-hydrofolate but is not essential in mice. J Biol Chem 2008; 283:25846-53.
150. Horie N, Aiba H, Oguro K, Hojo H, Takeishi K. Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5'-terminal regulatory region of the human gene for thymidylate synthase. Cell Struct Funct 1995; 20:191-97.
151. Ulrich CM, Bigler J, Velicer CM, Greene EA, Farin FM, Potter JD. Searching expressed sequence tag databases: Discovery and confirmation of a common polymorphism in the thymidylate synthase gene. Cancer Epidemiol Biomarkers Prev 2000; 9:1381-85.
152. Ulrich CM, Bigler J, Bostick R, Fosdick L, Potter JD. Thymidylate synthase promoter polymorphism, interaction with folate intake, and risk of colorectal adenomas. Cancer Res 2002; 62:3361-64.
153. Nief N, Le Morvan V, Robert J. Involvement of gene polymorphisms of thymidylate synthase in gene expression, protein activity and anticancer drug cytotoxicity using the NCI-60 panel. Eur J Cancer 2007; 43:955-62.
154. Mandola MV, Stoehlmacher J, Muller-Weeks S, Cesarone G, Yu MC, Lenz HJ, Ladner RD. A novel single nucleotide polymorphism within the 5' tandem repeat polymorphism of the thymidylate synthase gene abolishes USF-1 binding and alters transcriptional activity. Cancer Res 2003; 63:2898-904.
155. Wang L, Miao X, Tan W, Lu X, Zhao P, Zhao X, Shan Y, Li H, Lin D. Genetic polymorphisms in methylenetetrahydrofolate reductase and thymidylate synthase and risk of pancreatic cancer. Clin Gastroenterol Hepatol 2005; 3:743-51.
156. Kawakami K, Salonga D, Park JM, Danenberg KD, Uetake H, Brabender J, Omura K, Watanabe G, Danenberg PV. Different lengths of a polymorphic repeat sequence in the thymidylate synthase gene affect translational efficiency but not its gene expression. Clin Cancer Res 2001; 7:4096-101.
157. Calascibetta A, Cabibi D, Martorana A, Sanguedolce G, Rausa L, Feo S, Dardanoni G, Sanguedolce R. Thymidylate synthase gene promoter polymorphisms are associated with TSmRNA expressions but not with microsatellite instability in colorectal cancer. Anticancer Res 2004; 24:3875-80.
158. Chen J, Hunter DJ, Stampfer MJ, Kyte C, Chan W, Wetmur JG, Mosig R, Selhub J, Ma J. Polymorphism in the thymidylate synthase promoter enhancer region modifies the risk and survival of colorectal cancer. Cancer Epidemiol Biomarkers Prev 2003; 12:958-62.
159. Brown KS, Kluijtmans LA, Young IS, McNulty H, Mitchell LE, Yarnell JW, Woodside JV, et al. The thymidylate synthase tandem repeat polymorphism is not associated with homocysteine concentrations in healthy young subjects. Hum Genet 2004; 114:182-85.
160. Iacopetta B, Grieu F, Joseph D, Elsaleh H. A polymorphism in the enhancer region of the thymidylate synthase promoter influences the survival of colorectal cancer patients treated with 5-fluorouracil. Br J Cancer 2001; 85:827-30.
161. Villafranca E, Okruzhnov Y, Dominguez MA, Garcia-Foncillas J, Azinovic I, Martinez E, Illarramendi JJ, et al. Polymorphisms of the repeated sequences in the enhancer region of the thymidylate synthase gene promoter may predict downstaging after preoperative chemoradiation in rectal cancer. J Clin Oncol 2001; 19:1779-86.
162. Tsuji T, Hidaka S, Sawai T, Nakagoe T, Yano H, Haseba M, Komatsu H, et al.Polymorphism in the thymidylate synthase promoter enhancer region is not an efficacious marker for tumor sensitivity to 5-fluorouracil-based oral adjuvant chemotherapy in colorectal cancer. Clin Cancer Res 2003; 9:3700-04.
163. Ott K, Vogelsang H, Marton N, Becker K, Lordick F, Kobl M, Schuhmacher C, et al. The thymidylate synthase tandem repeat promoter polymorphism: A predictor for tumor-related survival in neoadjuvant treated locally advanced gastric cancer. Int J Cancer 2006; 119:2885-94.
164. Huang ZH, Hua D, Li LH. The polymorphisms of TS and MTHFR predict survival of gastric cancer patients treated with fluorouracil-based adjuvant chemotherapy in Chinese population. Cancer Chemother Pharmacol 2009; 63:911-18.
165. Chen M, Rahman L, Voeller D, Kastanos E, Yang SX, Feigenbaum L, Allegra C, Kaye FJ, Steeg P, Zajac-Kaye M. Transgenic expression of human thymidylate synthase accelerates the development of hyperplasia and tumors in the endocrine pancreas. Oncogene 2007; 26:4817-24.
166. Chango A, Emery-Fillon N, de Courcy GP, Lambert D, Pfister M, Rosenblatt DS, Nicolas JP. A polymorphism (80G^A) in the reduced folate carrier gene and its associations with folate status and homocysteinemia. Mol Genet Metab 2000; 70:310-15.
167. Whetstine JR, Gifford AJ, Witt T, Liu XY, Flatley RM, Norris M, Haber M, Taub JW, Ravindranath Y, Matherly LH. Single nucleotide polymorphisms in the human reduced folate carrier: Characterization of a high-frequency G/A variant at position 80 and transport properties of the His27 and Arg27 carriers. Clin Cancer Res 2001; 7:3416-22.
168. Morin I, Devlin AM, Leclerc D, Sabbaghian N, Halsted CH, Finnell R, Rozen R. Evaluation of genetic variants in the reduced folate carrier and in glutamate carboxypeptidase II for spina bifida risk. Mol GenetMetab 2003; 79:197-200.
169. Shaw GM, Zhu H, Lammer EJ, Yang W, Finnell RH. Genetic variation of infant reduced folate carrier (A80G) and risk of orofacial and conotruncal heart defects. Am J Epidemiol2003; 158:747-52.
170. O’Leary VB, Pangilinan F, Cox C, Parle-McDermott A, Conley M, Molloy AM, Kirke PN, Mills JL, Brody LC, Scott JM. Reduced folate carrier polymorphisms and neural tube defect risk. Mol Genet Metab 2006; 87:364-69.
171. Pei L, Zhu H, Ren A, Li Z, Hao L, Finnell RH, Li Z. Reduced folate carrier gene is a risk factor for neural tube defects in a Chinese population. Birth Defects Res A Clin Mol Teratol 2005; 73:430-33.
172. Pei L, Zhu H, Zhu J, Ren A, Finnell RH, Li Z. Genetic variation of infant reduced folate carrier (A80G) and risk of orofacial defects and congenital heart defects in China. Ann Epidemiol 2006; 16:352-56.
173. Baslund B, Gregers J, Nielsen CH. Reduced folate carrier polymorphism determines methotrexate uptake by B cells and CD4+ T cells. Rheumatology (Oxford) 2008; 47:451-53.
174. De Marco P, Calevo MG, Moroni A, Merello E, Raso A, Finnell RH, Zhu H, Andreussi L, Cama A, Capra V. Reduced folate carrier polymorphism (80A^G) and neural tube defects. Eur J Hum Genet 2003; 11:245-52.
175. Shaw GM, Lammer EJ, Zhu H, Baker MW, Neri E, Finnell RH. Maternal periconcep-tional vitamin use, genetic variation of infant reduced folate carrier (A80G), and risk of spina bifida. Am JMed Genet 2002; 108:1-6.
176. Coppede F, Marini G, Bargagna S, Stuppia L, Minichilli F, Fontana I, Colognato R, Astrea G, Palka G, Migliore L. Folate gene polymorphisms and the risk of Down syndrome pregnancies in young Italian women. Am J Med Genet A 2006; 140:1083-91.
177. Eklof V, Van Guelpen B, Hultdin J, Johansson I, Hallmans G, Palmqvist R. The reduced folate carrier (RFC1) 80G^A and folate hydrolase 1 (FOLH1) 1561C^T polymorphisms and the risk of colorectal cancer: A nested case-referent study. Scand J Clin Lab Invest2007; 21:1-9.
178. Laverdiere C, Chiasson S, Costea I, Moghrabi A, Krajinovic M. Polymorphism G80A in the reduced folate carrier gene and its relationship to methotrexate plasma levels and outcome of childhood acute lymphoblastic leukemia. Blood 2002; 100:3832-34.
179. Imanishi H, Okamura N, Yagi M, Noro Y, Moriya Y, Nakamura T, Hayakawa A, et al.Genetic polymorphisms associated with adverse events and elimination of methotrexate in childhood acute lymphoblastic leukemia and malignant lymphoma. J Hum Genet 2007; 52:166-71.
180. Zhao R, Russell RG, Wang Y, Liu L, Gao F, Kneitz B, Edelmann W, Goldman ID. Rescue of embryonic lethality in reduced folate carrier-deficient mice by maternal folic acid supplementation reveals early neonatal failure of hematopoietic organs. J Biol Chem2001; 276:10224-28.
181. Ma DW, Finnell RH, Davidson LA, Callaway ES, Spiegelstein O, Piedrahita JA, Salbaum JM, et al. Folate transport gene inactivation in mice increases sensitivity to colon carcinogenesis. Cancer Res 2005; 65:887-97.
182. Gelineau-van Waes J, Heller S, Bauer LK, Wilberding J, Maddox JR, Aleman F, Rosenquist TH, Finnell RH. Embryonic development in the reduced folate carrier knockout mouse is modulated by maternal folate supplementation. Birth Defects Res A Clin Mol Teratol 2008; 82:494-507.
183. Lawrance AK, Deng L, Brody LC, Finnell RH, Shane B, Rozen R. Genetic and nutritional deficiencies in folate metabolism influence tumorigenicity in Apcmin/+ mice. J Nutr Biochem 2007; 18:305-12.
184. Tsai G, Dunham KS, Drager U, Grier A, Anderson C, Collura J, Coyle JT. Early embryonic death of glutamate carboxypeptidase II (NAALADase) homozygous mutants. Synapse2003; 50:285-92.
185. Devlin AM, Ling EH, Peerson JM, Fernando S, Clarke R, Smith AD, Halsted CH. Glutamate carboxypeptidase II: A polymorphism associated with lower levels of serum folate and hyperhomocysteinemia. Hum Mol Genet 2000; 9:2837-44.
186. Lievers KJ, Kluijtmans LA, Boers GH, Verhoef P, den Heijer M, Trijbels FJ, Blom HJ. Influence of a glutamate carboxypeptidase II (GCPII) polymorphism (1561C^T) on plasma homocysteine, folate and vitamin B(12) levels and its relationship to cardiovascular disease risk. Atherosclerosis 2002; 164:269-73.
187. Melse-Boonstra A, Lievers KJ, Blom HJ, Verhoef P. Bioavailability of polyglutamyl folic acid relative to that of monoglutamyl folic acid in subjects with different genotypes of the glutamate carboxypeptidase II gene. Am J Clin Nutr 2004; 80:700-04.
188. Bacich DJ, Ramadan E, O’Keefe DS, Bukhari N, Wegorzewska I, Ojeifo O, Olszewski R, et al. Deletion of the glutamate carboxypeptidase II gene in mice reveals a second enzyme activity that hydrolyzes N-acetylaspartylglutamate. JNeurochem 2002; 83:20-29.
189. Ou X, Yang H, Ramani K, Ara AI, Chen H, Mato JM, Lu SC. Inhibition of human betaine-homocysteine methyltransferase expression by S-adenosylmethionine and methylthioadenosine. Biochem J 2007; 401:87-96.
190. Heil SG, Lievers KJ, Boers GH, Verhoef P, den Heijer M, Trijbels FJ, Blom HJ. Betaine-homocysteine methyltransferase (BHMT): Genomic sequencing and relevance to hyperhomocysteinemia and vascular disease in humans. Mol Genet Metab 2000; 71:511-19.
191. Weisberg IS, Park E, Ballman KV, Berger P, Nunn M, Suh DS, Breksa AP 3rd, Garrow TA, Rozen R. Investigations of a common genetic variant in betaine-homocysteine meth-yltransferase (BHMT) in coronary artery disease. Atherosclerosis 2003; 167:205-14.
192. Morin I, Platt R, Weisberg I, Sabbaghian N, Wu Q, Garrow TA, Rozen R. Common variant in betaine-homocysteine methyltransferase (BHMT) and risk for spina bifida. Am J Med Genet A 2003; 119:172-76.
193. Zhu H, Curry S, Wen S, Wicker NJ, Shaw GM, Lammer EJ, Yang W, Jafarov T, Finnell RH. Are the betaine-homocysteine methyltransferase (BHMT and BHMT2) genes risk factors for spina bifida and orofacial clefts? Am J Med Genet A 2005; 135:274-77.
194. Ananth CV, Elsasser DA, Kinzler WL, Peltier MR, Getahun D, Leclerc D, Rozen RR. Polymorphisms in methionine synthase reductase and betaine-homocysteine S-methyltransferase genes: Risk of placental abruption. Mol Genet Metab 2007; 91:104-10.
195. Xu X, Gammon MD, Zeisel SH, Lee YL, Wetmur JG, Teitelbaum SL, Bradshaw PT, Neugut AI, Santella RM, Chen J. Choline metabolism and risk of breast cancer in a population-based study. FASEB J 2008; 22:2045-52.
196. Xu X, Gammon MD, Wetmur JG, Bradshaw PT, Teitelbaum SL, Neugut AI, Santella RM, Chen J. B-vitamin intake, one-carbon metabolism, and survival in a population-based study of women with breast cancer. Cancer Epidemiol Biomarkers Prev 2008; 17:2109-16.
197. Ji C, Shinohara M, Vance D, Than TA, Ookhtens M, Chan C, Kaplowitz N. Effect of transgenic extrahepatic expression of betaine-homocysteine methyltransferase on alcohol or homocysteine-induced fatty liver. Alcohol Clin Exp Res 2008; 32:1049-58.
198. Johnson WG, Stenroos ES, Spychala JR, Chatkupt S, Ming SX, Buyske S. New 19 bp deletion polymorphism in intron-1 of dihydro folate reductase (DHFR): A risk factor for spina bifida acting in mothers during pregnancy? Am J Med Genet A 2004; 124A:339-45.
199. Gellekink H, Blom HJ, van der Linden IJ, den Heijer M. Molecular genetic analysis of the human dihydrofolate reductase gene: Relation with plasma total homocysteine, serum and red blood cell folate levels. Eur J Hum Genet 2007; 15:103-09.
200. van der Linden IJ, Nguyen U, Heil SG, Franke B, Vloet S, Gellekink H, den Heijer M, Blom HJ. Variation and expression of dihydrofolate reductase (DHFR) in relation to spina bifida. Mol Genet Metab 2007; 91:98-103.
201. Xu X, Gammon MD, Wetmur JG, Rao M, Gaudet MM, Teitelbaum SL, Britton JA, Neugut AI, Santella RM, Chen J. A functional 19-base pair deletion polymorphism of dihydrofolate reductase (DHFR) and risk of breast cancer in multivitamin users. Am J Clin Nutr 2007; 85:1098-102.
202. Parle-McDermott A, Pangilinan F, Mills JL, Kirke PN, Gibney ER, Troendle J, O’Leary VB, et al. The 19-bp deletion polymorphism in intron-1 of dihydrofolate reductase (DHFR) may decrease rather than increase risk for spina bifida in the Irish population. Am J Med Genet A 2007; 143:1174-80.